Advertisement for orthosearch.org.uk
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

SURGEON-LED BIOPSY WITH INTRAOPERATIVE FROZEN SECTION IS AN ACCURATE AND COST EFFECTIVE METHOD FOR INITIAL EVALUATION OF MUSCULOSKELETAL SARCOMAS.



Abstract

Introduction: The most appropriate protocol for biopsying musculoskeletal tumours is controversial. Some authors advocate the use of CT-guided core biopsy. At the Royal Prince Alfred Hospital, Sydney, Australia, initial biopsies of most musculoskeletal tumours involve a surgeon-led operative core biopsy technique with frozen section evaluation. The latter is used to determine whether diagnostic tissue has been obtained and, if possible, to establish a definitive diagnosis.

Aims: To determine the accuracy and cost effectiveness of a surgeon-led biopsy protocol for biopsying musculoskeletal tumours.

Methods: A retrospective audit of biopsies of musculoskeletal tumours performed in the bone and soft tissue sarcoma unit at the Royal Prince Alfred Hospital over a two year period was performed.

Results: One hundred and four patients had biopsies performed under the protocol. There were no non-diagnostic biopsies and one minor error resulting in no change in the patient’s management. There was no requirement to re-biopsy any of the patients. A surgeon-led operative core biopsy with frozen section evaluation was 38% more costly than a CT-guided core biopsy (AU$1804 versus AU$1308).

Conclusions: Surgeon-led biopsy with intra-operative frozen section evaluation is effective and accurate and, despite being labour intensive, the reduction in the need for repeat biopsies justifies its use. Whilst the technique is approximately 38% more costly, there is no requirement for re-biopsy and anxiety associated with the need for this is allayed.

Correspondence should be addressed to Ms Larissa Welti, Scientific Secretary, EFORT Central Office, Technoparkstrasse 1, CH-8005 Zürich, Switzerland